Trial Profile
Hydronidone for the Treatment of Liver Fibrosis Associated With Chronic Hepatitis B:Randomized,Double-blind,Placebo-controlled,Entecavir Basic Treatment,Multicentre Phase 3 Trial.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Hydronidone (Primary)
- Indications Hepatic fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Continent Pharmaceutical
- 26 Mar 2024 According to Gyre Therapeutics media release, the company expects to report topline data from Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in 2025.
- 17 Feb 2022 Status changed from not yet recruiting to recruiting.
- 29 Oct 2021 Status changed from planning to not yet recruiting.